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Abstract 24 
African swine fever (ASF) is an emerging disease threat for the swine industry worldwide. No 25 
ASF vaccine is available and progress is hindered by lack of knowledge concerning the extent of 26 
ASF virus (ASFV) strain diversity and the viral antigens conferring type-specific protective 27 
immunity in pigs. Previously, we demonstrated that ASFV serotype specific proteins CD2v 28 
(EP402R) and/or C-type lectin (EP153R) are important for protection against homologous ASF 29 
infection.  Here, we identified six discrete T-cell epitope regions present on CD2v and C-type 30 
lectin using IFN-γ ELISpot assay and PBMCs from ASF immune animals, indicating cellular 31 
reactivity to these proteins in the context of ASFV infection and protective immunity. Notably, 32 
three of the epitope regions map to previously described serotype-specific signature regions of 33 
these proteins. Improved understanding of ASFV protective antigens, relevant epitopes and their 34 
diversity in nature will facilitate ASFV subunit vaccine design and development.  35 
 36 
Keywords 37 
C-type lectin, CD2v, T-cell epitopes, African swine fever virus, protective immunity 38 
 39 
Abbreviations 40 
ASF, African swine fever; ASFV, African swine fever virus; HAI, hemadsorption-inhibition; M-41 
II, monocyte infection-inhibiting; HAU, hemadsorbing unit; DPC, days post challenge; IFN-γ, 42 
interferon gamma; PHA, phytohemagglutinin; AA, amino acids; SLA, swine leukocyte antigen 43 
 44 
 ASF is an acute viral hemorrhagic disease affecting domestic swine with mortality rates 45 
approaching 100% (1-3). Devastating ASF outbreaks and continuing epidemic in the Caucasus 46 
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region, the Russia Federation, the Baltic states, countries of Eastern Europe and now China 47 
(2007 – to date) highlight the significance of this disease threat (4, 5). No ASF vaccine is 48 
available, though protection against homologous virus challenge has been observed (6-12). 49 
Vaccine development and disease control progress is hindered by lack of knowledge concerning 50 
the ASF virus (ASFV) antigens responsible for inducing protective immunity and concerning the 51 
diversity of these protective antigens in nature.  52 
 Protective immunity against ASFV remains poorly defined. As is the case with most viral 53 
infections, both humoral and cellular immune responses appear to be important for protection. 54 
While the passive transfer of anti-ASFV antibodies is protective, the effector mechanisms remain 55 
undefined (13-15). ASFV neutralizing antibodies have been described (16-19), but their cross 56 
neutralization in vitro does not correlate with ASFV cross protection in pigs (17, 20). ASF 57 
protective immunity may be serotype-specific, as viruses within a hemadsorption-inhibition 58 
(HAI) serogroup appear to cross protect against one another while viruses outside the serogroup 59 
do not  (21- 24; Malogolovkin et al. unpublished data).  Interestingly, anti-ASFV “monocyte 60 
infection-inhibiting (M-II) antibodies” inhibit ASFV replication in macrophage cell cultures (7) 61 
but only against homologous ASFV strains and in a manner correlating with cross-protective 62 
immunity in vivo (25, 26).   63 
 Multiple data support a role for cellular immune responses in ASFV protective immunity. 64 
Lymphocyte depletion of pigs indicate that cytotoxic CD8+ lymphocytes are important for 65 
ASFV clearance and protection (27), and that protective effects are correlated with ASFV strain-66 
specific CD8+ T-cell responses (28, 29). Additionally, lack of detectable anti-ASFV antibodies 67 
at the time of challenge in DNA-vaccinated and partially protected animals has been interpreted 68 
as support for the role of cellular immunity in protection (28, 29). Thus, no definitive correlates 69 
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of protection are established and no specific viral protein(s) has been shown sufficient for 70 
induction of robust protective immunity in pigs.  71 
 Recently, we have shown that two ASFV-encoded proteins, CD2v (EP402R) and/or C-type 72 
lectin (EP153R), are sufficient for mediating serologic specificity as determined by HAI (30). 73 
ASFV CD2v is the only known viral homolog of cellular CD2, a T-Cell protein involved in co-74 
regulation of cell activation. CD2v is the ASFV hemagglutinin and has been implicated 75 
previously in protective immunity (31, 32, 33). Pigs immunized with CD2v developed HAI and 76 
M-II antibodies and were partially protected from challenge with the homologous virulent virus 77 
strain (34). CD2v expression was also required for partial protection conferred by subunit ASF 78 
vaccine constructs (28, 35). Additional support for a CD2v role in protective immunity comes 79 
from vaccine studies using ASFV chimeric viruses; homologous CD2v and/or the adjacent C-80 
type lectin protein were necessary for protection against homologous ASFV infection (36). Thus, 81 
CD2v and C-type lectin proteins may represent significant protective antigens for ASFV that 82 
should be targeted for vaccine design and development; the viral protein domains and epitopes 83 
associated with protective host responses remain to be defined.  Recent studies indicate that 84 
heterologous expression of CD2v and C-type lectin proteins in swine can induce specific T-cell 85 
responses (37, 38). Here, we have identified T-cell epitope regions from CD2v and C-type lectin 86 
proteins which induce T-cell responses in the context of ASF protective immunity.  87 
 To ensure that T-cell responses against CD2v and C-type lectin proteins were evaluated in 88 
the context of ASF protective immunity, ASFV immune animals were generated using a 89 
previously described vaccination protocol (36). The virulent ASFV isolate Congo K-49, an HAI 90 
serogroup 2 virus, and cell culture-passed, attenuated derivative Congo KK-262 virus, were used 91 
for the inoculation of animals in biosecure animal facilities (Federal Research Center of Virology 92 
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and Microbiology, Pokrov, Russia) in accordance with Russian legislation and under the 93 
supervision of the Center’s Research Ethics Committee. In three independent experiments, 94 
Landrace and Large White pigs (30 to 35 kg) were mock vaccinated or vaccinated 95 
intramuscularly with 106 hemadsorbing units (HAU) of attenuated Congo KK-262 and boosted 96 
with the same dose at 21 days post-vaccination. Three weeks later, animals were challenged 97 
intramuscularly with 103 HAU of virulent Congo K-49 and monitored for 30 days. Clinical signs, 98 
survival rate and time-to-death were recorded as described previously (36). Blood samples were 99 
collected at regular intervals post vaccination and for 30 days post challenge (DPC). Quantitative 100 
PCR of ASFV in blood samples was performed as previously described (39). ASFV ELISA 101 
assays were performed as recommended by the manufacturer (IDScreen® African Swine Fever 102 
Indirect, France) using serum collected just prior to challenge infection. 103 
 Across three independent experiments, animals immunized with Congo-attenuated (KK-104 
262) virus demonstrated solid levels of protection when challenged with virulent Congo K-49; 105 
immunized animals survived infection exhibiting only transient fever responses and reduced 106 
viremia compared to control animals (Table 1).  At the time of challenge, all KK-262 immunized 107 
animals were serologically positive for ASFV-specific antibodies. From these ASFV Congo K-108 
49 immune animals, peripheral blood mononuclear cells (PBMC) were isolated seven to ten days 109 
post-challenge by density gradient centrifugation using Histopaque 1077 (Sigma-Aldrich). Buffy 110 
coats were collected, resuspended in RPMI-1640 with 10% fetal bovine serum and either used 111 
immediately or stored frozen at −80°C until use in in vitro cellular assays. 112 
 To examine swine T-cell responses against discrete regions of the ASFV CD2v and C-type 113 
lectin proteins, IFN-γ ELISpot assays were designed to assess responses of immune cells to short 114 
peptides of each protein. To assess individual, potentially antigenic sequences of the CD2v and 115 
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C-type lectin proteins, a library of 132 overlapping (each by 11 amino acids) 15-mer peptides 116 
were designed based on a conceptual fusion of Congo K-49 C-type lectin and CD2v protein 117 
sequences (Supplemental Table 1). Peptides were synthesized by Genemed Synthesis, Inc (San 118 
Antonio, USA), resuspended in DMSO (100 mg/ml), aliquoted and stored at −80°C for later use 119 
as antigens in in vitro assays.  120 
 To assess reactivity of immune cells against K-49 CD2v and C-type lectin protein peptides, 121 
PBMC were assayed using IFN-γ ELISpot.  ELISpot kit and protocols (BD Bioscience #551849) 122 
were used incorporating a mouse anti-Pig IFN- capture antibody (BD Bioscience #559961) and 123 
biotin-labeled mouse anti-pig IFN- primary antibody (BD Bioscience #559958). PBMC 124 
(1.2x106 cells/well) were cultured in duplicate with pooled or individual CD2v or C-type lectin 125 
peptides  (2 to 5 μg/ml) for 18-20 h (37 C and 5% CO2) in plates coated with capture antibody. 126 
Cells were removed, biotinylated detection antibody was added, and plates were developed with 127 
streptavidin–peroxidase and substrate using manufacturer’s recommended protocols. Frequencies 128 
of IFN-γ- secreting cells recognizing individual CD2v or C-type lectin peptides were calculated 129 
by subtracting the number of spots in unstimulated wells from numbers in peptide-stimulated 130 
wells, and expressed as number of responding cells/106 PBMC. Controls included both 131 
unstimulated (negative control) and PHA-stimulated (positive control) immune cells, as well as 132 
peptide-stimulated cells from an ASFV naïve animal. Quantitative data were analyzed using the 133 
Two-way ANOVA test as implemented in GraphPad Prizm 7 (La Jolla, USA, graphpad.com).  134 
 ELISpot assays indicated reactivity against CD2v and C-type lectin protein peptides in 135 
ASFV-immune swine cells, but not in unstimulated cells or peptide-stimulated cells from naïve 136 
animals. Initial screenings of immune cells were conducted against pools of overlapping CD2v 137 
and C-type lectin peptides. Peptides from pools demonstrating initial reactivity were then used 138 
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individually to fine-map T-cell epitope regions demonstrating reactivity for each protein using 139 
PBMCs from multiple animals (Fig.1 and Table 2).  140 
 Six discrete T-cell epitope regions (Regions I-VI) were identified within C-type lectin and 141 
CD2v proteins, consisting of two to four overlapping peptide each (Table 2). Regions I and II 142 
were located in the carboxyl-terminal, extracellular domain of the C-type lectin protein (Fig. 1), 143 
a region previously identified as containing a serogroup-specific signature (30). In regions I and 144 
II, positive reactivity was observed for multiple overlapping peptides in approximately 70% of 145 
animals tested (Table 2). Four T-cell epitope regions (III-VI) were identified in CD2v, two 146 
located within the amino-terminal immunoglobulin-like domain and two within the proline-rich 147 
cytoplasmic domain of the protein (Fig. 1). Positive reactivity was observed for three to four 148 
overlapping peptides each within regions III-VI, and responses to individual peptides were 149 
detected in 40–100% of the animals tested (Table 2).    150 
 To examine relative potential for different epitope regions to contribute to serospecific 151 
cross-protective immunity, immunoreactive peptide sequences and consensus sequences of the 152 
six T-cell epitope regions identified for Congo K-49 (serogroup 2 virus) were compared with C-153 
type lectin and CD2v sequences from ASFV identified as non-serogroup 2 based on HAI 154 
signature sequence comparison as previously described (30).  Epitope conservation and cluster 155 
analysis were carried out with the Immune Epitopes database and analysis resources available on 156 
www.iedb.org.  157 
Regions I and II, mapping to the carboxyl–terminal, extracellular domain of the C-type lectin 158 
protein, exhibited the greatest degree of variability with 27-80% amino acid (AA) identity 159 
between Congo K-49 peptides (or epitope region consensus) and sequences of non-serotype 2 160 
viruses. Regions III and IV, mapping to the immunoglobulin domain of CD2v, were less variable 161 
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with a range of approximately 40-80% AA identity observed.  Notably, Regions V and VI, 162 
mapping within the proline-rich cytoplasmic domain of CD2v were more conserved (79-100% 163 
AA identity) than regions I-IV between ASFV serotypes (Fig 1 and Table 2). A previously 164 
identified CD2v T-cell epitope for the ASFV isolate E75, a serogroup 4 virus, appears to 165 
partially overlap Region III (4 AA with 50% identity) as well (28); whether this represents a true 166 
Region III epitope or an additional adjacent epitope on the ASFV E75 CD2v protein remains to 167 
be determined. Nevertheless, this region of the protein appears to be a reactive T-cell epitope in 168 
two HAI serologically distinct viruses. 169 
 Without empirical data, identification of T-cell epitopes is limited to prediction based on 170 
computational models and algorithms. To compare performance of C-type lectin and CD2v 171 
epitope prediction against mapped reactive peptides, artificial neural network and support vector 172 
machine methods were used to predict potential T-cell epitopes using the CTLPred web server 173 
(40). Only two of the T-cell epitope regions identified experimentally in this study were 174 
predicted computationally as containing T-cell epitopes. One epitope in Region III and multiple 175 
overlapping epitopes (9 AA each) within Region III, were predicted as shown in (Table 2).  176 
 Overall, results described here have identified six novel T-cell epitope regions on ASFV 177 
serotype-specific proteins CD2v and C-type lectin with multiple overlapping peptides for each 178 
epitope region being recognized by approximately 50-100% of immune animals tested.  Robust 179 
responses of T-cells to these epitopes, in immune animals seven to ten days post challenge, 180 
suggest their significance for the observed protective host response (Table1).  181 
 T-cell responses observed in these experiments potentially include both CD8+ and CD4+ 182 
responses. T-cell epitope regions identified ranged from 19 to 27 AA; sizes consistent with 183 
presentation via either SLA I or SLA II molecules where optimal peptide sizes range from 8-10 184 
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AA and 18-20 AA, respectively (41, 42). Conceivably, these regions could contain multiple 185 
epitopes; for example, computer predictions identified four overlapping T-cell epitopes (of 9 186 
AA) in Region III within the CD2v protein.  187 
 The modest degree of conservation observed for epitope regions I through IV with 188 
homologous regions from other ASFV serogroups and unassigned viruses together with the fact 189 
that Regions I, II and IV are located within previously identified serogroup-specific signature 190 
regions of these proteins  (30)  suggest that T-cell epitopes also are specific for a given viral 191 
serotype and that T-cell host responses may be associated with the serotype-specific protection 192 
observed.  193 
 While CD2v has been implicated previously as a potential protective ASFV antigen (28, 194 
34-36), only recently has the C-type lectin protein been considered a candidate (36).   The robust 195 
host responses to epitope Regions I and II located within the carboxyl-terminal regions of the C-196 
type lectin protein are notable for two reasons: the two epitope regions are significantly variable 197 
between ASFV serogroups, and a high percentage of immune animals tested (54-76%) 198 
responded to individual peptides contained within these regions. Given this result and prior 199 
vaccine studies where homologous CD2v and/or C-type lectin protein were necessary for 200 
protection against homologous ASFV infection (36), additional evaluation of this protein as a 201 
protective antigen is warranted.  202 
 Surprisingly, strong T-cell responses were observed for epitope regions V and VI 203 
contained within the proline–rich cytoplasmic domain of CD2v (Fig. 1, Table 2). Despite repeat 204 
variation in the CD2v cytoplasmic domain, sequences representing the reactive peptides 205 
identified here are in fact highly conserved among ASF viruses and across HAI serogroups. The 206 
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significance of this response for protective immunity or possible immunopathology in vaccinated 207 
but unprotected animals remains to be determined. 208 
 In summary, we have identified novel T-cell epitopes on ASFV serotype-specific proteins 209 
CD2v and C-type lectin. Improved understanding of ASFV protective antigens, relevant epitopes 210 
and their diversity in nature will facilitate ASFV subunit vaccine design and development.  211 
 212 
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Table 1. Vaccination with attenuated Congo KK-262 induces protection against virulent Congo K-49 challenge
Pre-challenge Maximal viral
(%) TTD
#
serology, % positive
§
load (genomes/ml)
§§
Experiment 1
KK-262/K-49
* 7 0 - 4.4 (0.9) 100 5.4e+002 (0.3)
K-49
** 3 100 4.3 (0.5) 3.3 (0.5) 0 5.9e+008 (0.1)
Experiment 2
KK-262/K-49 3 0 - 3.3 (0.5) 100 4.6e+002 (0.4)
K-49 3 100 6.6 (0.6) 3.3 (0.5) 0 7.8e+008 (0.2)
Experiment 3
KK-262/K-49 3 0 - 3.6 (0.5) 100 7.0e+002 (0.5)
K-49 3 100 6.3 (0.6) 3 (0.0) 0 9.1e+009 (0.2)
#  TTD,  time to death, in mean days post-challenge, with standard error (SE) in parenthesis.
## TTF, time to onset of fever, in mean days post-challenge, with SE in parenthesis.
§  As determined by ELISA (IDScreen® African Swine Fever Indirect, France); percent (%) of animals with positive result.
§§  Mean maximal viral load in log10 viral genomic copies (ml blood
-1 ), with SE in parenthesis.
*  Animals were vaccinated with Congo-attenuated virus (KK-262) followed by challenge with Congo-virulent virus (K-49).
** Animals were mock vaccinated followed by challenge with Congo-virulent virus (K-49).
n
Mortality
TTF
##
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Table 2.  T-cell epitopes in ASFV Congo K-49 CD2v and C-type lectin proteins. 392 
 
Epitope 
Region1 
 
Peptide 
No2 
 
Peptide sequence3 
No. animals 
positive/tested 
(%)4 
Min-Max 
aa Id, other 
serogroups5 
Predicted/ 
Previously 
mapped 6 
 
I 
(Lec) 
29 
30 
31 
32 
Cons 
SFLNLTKLYHHHSHY 
    LTKLYHHHSHYWVNY 
        YHHHSHYWVNYSLNN 
            SHYWVNYSLNNNYSV 
SFLNLTKLYHHHSHYWVNYSLNNNYSV 
10/13 (76%) 
9/13 (69%) 
9/13 (69%) 
7/13 (54%) 
47%-60% 
47%-73% 
40%-80% 
33%-80% 
42%-74% 
 
 
II 
(Lec) 
37 
38 
Cons 
KYNLNRKKSHYTDLL 
    NRKKSHYTDLLFICS 
KYNLNRKKSHYTDLLFICS 
6/8 (75%) 
6/8 (75%) 
27%-33% 
27%-40% 
27%-55% 
 
 
III 
(CD2v) 
51 
52 
54 
Cons 
INSETEGIFWNFYNN 
    TEGIFWNFYNNTFNT 
            YNNTFNTIATCGKKN 
INSETEGIFWNFYNNTFNTIATCGKKN 
2/4 (50%) 
2/4 (50%) 
2/5 (40%) 
33%-67% 
40%-70% 
33%-80% 
26%-67% 
 
FYNNTFNTI 
 
 
IV 
(CD2v) 
66 
68 
69 
Cons 
TYQLVYSRNRINYTI 
        NRINYTINLLLPVTS 
            YTINLLLPVTSPIIT 
TYQLVYSRNRINYTINLLLPVTSPIIT 
3/5 (60%) 
2/4 (50%) 
2/4 (50%) 
47%-73% 
53%-87% 
53%-93% 
48%-81% 
VYSRNRINY 
SRNRINYTI 
NRINYTINL 
RINYTINLL 
F3:SVDSPTITY 
 
V 
(CD2v) 
117 
118 
119 
120 
Cons 
PLNPSPPPKPCPPPK 
    SPPPKPCPPPKPCPP 
        KPCPPPKPCPPPKPC 
            PPKPCPPPKPCPPPK 
PLNPSPPPKPCPPPKPCPPPKPCPPPK 
3/7 (43%) 
5/7 (71%) 
5/7 (71%) 
3/7 (43%) 
73%-100% 
93%-100% 
93%-100% 
93%-100% 
74%-100% 
 
 
VI 
(CD2v) 
127 
128 
129 
130 
Cons 
YSPPKPLPSIPLLPN 
    KPLPSIPLLPNIPPL 
        SIPLLPNIPPLSTQN 
            LPNIPPLSTQNISLI 
YSPPKPLPSIPLLPNIPPLSTQNISLI 
2/4 (50%) 
 4/4 (100%) 
2/4 (50%) 
2/4 (50%) 
53%-100% 
73%-100% 
87%-100% 
87%-100% 
74%-100% 
 
1 Epitope Region, T-cell epitope regions identified by ELISPOT reactivity to multiple, 393 
overlapping peptides.  Regions I-II represent sequences in C-type lectin-like (Lec) protein, 394 
Regions III-VI represent sequences in CD2v (CD2v). 395 
2 Peptide no., (see Supplemental Table 1). 396 
3 Peptide sequence, amino acid sequence of reactive peptide. Cons, consensus of all peptide 397 
sequences in the region. 398 
4 No. animals positive/tested (%), total number of swine testing positive versus the total number 399 
of swine tested over three independent experiments, with the percent positive indicated in 400 
parentheses. 401 
5 Min-Max aa Id, other serogroups. Lower and upper range of amino acid identity (aa Id) 402 
between peptide and consensus sequences and sequences in ASFV which phylogenetically fall 403 
outside of the lectin/CD2v serogroup 2 cluster (30). 404 
6 Predicted/Previously mapped. In silico-predicted epitopes matching within empirically 405 
identified epitope regions I-VI. Also listed is the F3 epitope previously identified in ASFV strain 406 
E-75 CD2v (28), overlapping here in epitope region II and with conserved amino acids indicated 407 
by underlining. 408 
 409 
 410 
 411 
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Fig. 1. Identification of T-cell epitopes in ASFV serotype-specific proteins. 412 
Pigs were immunized with attenuated Congo KK-262 and subsequently challenged with virulent 413 
Congo K-49. PBMCs were isolated 7 to 10 days post-challenge, incubated with CD2v and C-414 
type lectin overlapping 15-mer peptides, and assayed by IFN-γ-ELISpot as described in the text. 415 
Peptide numbers are indicated in the x-axis and polypeptide regions to which the peptides map 416 
are shown schematically below. Black and grey bars represent number of tested pigs and 417 
ELISpot-reactive pigs, respectively. Roman numbers (I-VI) above bar clusters indicate the six T-418 
cell epitope regions identified. Small circles above the bars represent average numbers of spot 419 
forming units (SFU) from 1.2e+006 PBMCs. The dotted line represents the mean SFU in control 420 
(non-stimulated) PBMCs plus two SE. 421 
Figure 1 Click here to access/download;Figure;Figure 1_final.eps
Supplemental Table 1. ASFV strain K-49 C-type lectin and CD2v fusion protein peptides 
used for T-cell epitope mapping (Burmakina et al., 2018) 
 
Peptide number  Peptide sequence  Peptide number  Peptide sequence 
1	 MAFLNKKYIGLINKK 67	 VYSRNRINYTINLLL 
  2  NKKYIGLINKKEGLK  68  NRINYTINLLLPVTS   
3	 IGLINKKEGLKKKID 69	 YTINLLLPVTSPIIT 
  4  NKKEGLKKKIDDYSI  70  LLLPVTSPIITYNCT   
5	 GLKKKIDDYSILIIG 71	 VTSPIITYNCTQSLI 
  6  KIDDYSILIIGILIG  72  IITYNCTQSLITCEK   
7	 YSILIIGILIGTNIL 73	 NCTQSLITCEKTNGT 
  8  IIGILIGTNILSLII  74  SLITCEKTNGTNIRL   
9	 LIGTNILSLIINIIG 75	 CEKTNGTNIRLFLNL 
  10  NILSLIINIIGEINK  76  NGTNIRLFLNLNDTI   
11	 LIINIIGEINKPICY 77	 IRLFLNLNDTINEYT 
  12  IIGEINKPICYQNDD  78  LNLNDTINEYTNKSF   
13	 INKPICYQNDDKIFY 79	 DTINEYTNKSFLNYY 
  14  ICYQNDDKIFYCPKD  80  EYTNKSFLNYYWNSS   
15	 NDDKIFYCPKDWVGY 81	 KSFLNYYWNSSELNN 
  16  IFYCPKDWVGYNNVC  82  NYYWNSSELNNIFLA   
17	 PKDWVGYNNVCYYFS 83	 NSSELNNIFLATCII 
  18  VGYNNVCYYFSNDNG  84  LNNIFLATCIINNTL   
19	 NVCYYFSNDNGNNYT 85	 FLATCIINNTLNSAN 
  20  YFSNDNGNNYTTADN  86  CIINNTLNSANTTKV   
21	 DNGNNYTTADNKCKQ 87	 NTLNSANTTKVINCT 
  22  NYTTADNKCKQLNNS  88  SANTTKVINCTNPLL   
23	 ADNKCKQLNNSTLAN 89	 TKVINCTNPLLKSYQ 
  24  CKQLNNSTLANNLTD  90  NCTNPLLKSYQNYFL   
25	 NNSTLANNLTDLLNL 91	 PLLKSYQNYFLENIH 
  26  LANNLTDLLNLTSFL  92  SYQNYFLENIHTLFY   
27	 LTDLLNLTSFLNLTK 93	 YFLENIHTLFYMIIF 
  28  LNLTSFLNLTKLYHH  94  NIHTLFYMIIFIVSG   
29	 SFLNLTKLYHHHSHY 95	 LFYMIIFIVSGITIS 
  30  LTKLYHHHSHYWVNY  96  IIFIVSGITISIFIS   
31	 YHHHSHYWVNYSLNN 97	 VSGITISIFISIITF 
  32  SHYWVNYSLNNNYSV  98  TISIFISIITFLSLR   
33	 VNYSLNNNYSVPLID 99	 FISIITFLSLRKRKK 
  34  LNNNYSVPLIDSKYN  100  ITFLSLRKRKKHVEE   
35	 YSVPLIDSKYNLNRK 101	 SLRKRKKHVEEIESP 
  36  LIDSKYNLNRKKSHY  102  RKKHVEEIESPPPSE   
37	 KYNLNRKKSHYTDLL 103	 VEEIESPPPSESNEE 
  38  NRKKSHYTDLLFICS  104  ESPPPSESNEEDISH   
39	 SHYTDLLFICSKGGG 105	 PSESNEEDISHDDTT 
  40  DLLFICSKGGGGSII  106  NEEDISHDDTTSIHE   
41	 ICSKGGGGSIIKLIF 107	 ISHDDTTSIHEPSPR 
  42  GGGGSIIKLIFLICF  108  DTTSIHEPSPREPLL   
43	 SIIKLIFLICFKIVL 109	 IHEPSPREPLLPKPY 
  44  LIFLICFKIVLSINY  110  SPREPLLPKPYSRYQ   
Supplemental data Click here to access/download;Supplementary Material
Files;2018.Burmakina_ASFV_Supplemental_1.pdf
45	 ICFKIVLSINYWVRY 111	 PLLPKPYSRYQYNTP 
  46  IVLSINYWVRYNDTV  112  KPYSRYQYNTPIYYM   
47	 INYWVRYNDTVTLNS 113	 RYQYNTPIYYMRPST 
  48  VRYNDTVTLNSNINS  114  NTPIYYMRPSTQPLN   
49	 DTVTLNSNINSETEG 115	 YYMRPSTQPLNPSPP 
  50  LNSNINSETEGIFWN  116  PSTQPLNPSPPPKPC   
51	 INSETEGIFWNFYNN 117	 PLNPSPPPKPCPPPK 
  52  TEGIFWNFYNNTFNT  118  SPPPKPCPPPKPCPP   
53	 FWNFYNNTFNTIATC 119	 KPCPPPKPCPPPKPC 
  54  YNNTFNTIATCGKKN  120  PPKPCPPPKPCPPPK   
55	 FNTIATCGKKNNVCE 121	 CPPPKPCPPPKPCPP 
  56  ATCGKKNNVCECSNY  122  KPCPPPKPCPPPKPC   
57	 KKNNVCECSNYDNSL 123	 PPKPCPPPKPCPSPE 
  58  VCECSNYDNSLYNIT  124  CPPPKPCPSPESYSP   
59	 SNYDNSLYNITNNCS 125	 KPCPSPESYSPPKPL 
  60  NSLYNITNNCSLTIF  126  SPESYSPPKPLPSIP   
61	 NITNNCSLTIFPNNT 127	 YSPPKPLPSIPLLPN 
  62  NCSLTIFPNNTKIFN  128  KPLPSIPLLPNIPPL   
63	 TIFPNNTKIFNTTYQ 129	 SIPLLPNIPPLSTQN 
  64  NNTKIFNTTYQLVYS  130  LPNIPPLSTQNISLI   
65	 IFNTTYQLVYSRNRI 131	 PPLSTQNISLIHVDR 
  66  TYQLVYSRNRINYTI  132  TQNISLIHVDRII   
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